This past Wednesday an FDA panel voted not to approve Lilly’s Jardiance as an add-on therapy for patients with Type 1 diabetes. We weren’t surprised by this vote as quite frankly the data wasn’t overly compelling. What did check our eye was this from a company issued press release;
"With about 40,000 Americans diagnosed with type 1 diabetes every year, we see today's meeting as an important means of elevating the discussion around the challenges of managing blood sugar levels for those with type 1 diabetes and the need for new treatment options," said . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.